Stephen Wanaski, PhD – Senior Vice President, Research & Exploratory Development
Stephen Wanaski serves as Senior Vice President of Research and Exploratory Development at Paragon Biosciences, overseeing the basic science, pharmacology/toxicology, clinical pharmacology, and due diligence activities for drug candidates and technologies across portfolio companies.
Dr. Wanaski brings a wealth of experience to Paragon including orphan drug development of small and large molecules from discovery through late-stage clinical studies and approval.
Previously, Dr. Wanaski served as Vice President of Research & Exploratory Development at Castle Creek Pharmaceuticals, a Paragon portfolio company. He held the same role at Marathon Pharmaceuticals, playing an integral role in the development and FDA approval of a treatment for Duchenne muscular dystrophy. Prior to Marathon, Dr. Wanaski was Vice President of Research & Development at NeuroTherapeutics Pharma. He led preclinical and clinical pharmacology development at Ovation Pharmaceuticals (acquired by Lundbeck) and was responsible for late-stage new drug application (NDA)-enabling activities for four, first cycle NDA approvals in various central nervous indications. He also worked at an oncology-based biotech company, NeoPharm. Dr. Wanaski received a bachelor’s degree from the University of Notre Dame and earned his Ph.D. in biochemistry from the University of Illinois in Urbana-Champaign.